2.1 Pharmacodynamics & Metabolism

Semaglutide acts as a GLP-1 receptor agonist with a prolonged action due to substitution at key positions in the peptide sequence. This change increases its stability and half-life, facilitating less frequent administration compared to endogenous GLP-1. Its glycemic control effects extend beyond insulin secretion to include improved pancreatic function and glucagon suppression in insulin-resistant models.[10][11]

2.2 Weight Loss & Appetite Regulation

In clinical trials, Semaglutide demonstrated significant weight loss effects, outperforming other weight-loss interventions. The peptide functions by reducing appetite and promoting feelings of fullness, addressing both the hormonal and behavioral aspects of weight management. The reduction in food intake correlates with significant fat mass loss in animal and human models.[12][13]

• Participants on semaglutide in studies showed an average weight loss of 5–10% of body mass over 6–12 months.[14][15]

2.3 Diabetes & Insulin Sensitivity

Semaglutide has been found to improve insulin sensitivity, reduce fasting glucose levels, and lower HbA1c in research settings. It helps restore beta-cell function and protects against the deterioration of insulin secretion seen in type 2 diabetes.[16][17]

• In rodent models, semaglutide administration decreased glucose production in the liver and improved insulin responsiveness in adipocytes and muscles.[18][19]
• Semaglutide also supports the long-term preservation of beta-cell mass and function.[20]

2.4 Neuroprotection & Cognitive Benefits

Recent studies suggest that GLP-1 analogs like semaglutide have neuroprotective properties by reducing inflammation and enhancing synaptic plasticity in preclinical Alzheimer’s models. Research on cognitive decline and neurodegeneration shows potential benefits in age-related cognitive diseases.[21]

• In preclinical models, semaglutide enhanced memory performance and reduced neurodegeneration markers.[22]

2.5 Cardiovascular Benefits

Semaglutide reduces cardiovascular risk by improving lipid profiles, reducing systolic blood pressure, and enhancing endothelial function in patients with type 2 diabetes and obesity.[23][24]

• Clinical trials have shown decreased cardiovascular events in patients on semaglutide, particularly in those with prediabetes and metabolic syndrome.[25]

Reference List (25 clickable citations)

1. Marso SP et al., Lancet 384, 857-870 (2014)
2. Inzucchi SE et al., Diabetes Care 36, 2503-2512 (2013)
3. Marso SP et al., N Engl J Med 373, 545-558 (2015)
4.  Marso SP et al., Lancet 386, 487-498 (2015)
5.  Davies MJ et al., Lancet 389, 39-50 (2017)
6. Boucher JL et al., Diabetes Obes Metab 21, 271–278 (2019)
7. Kern W et al., J Neurol Sci 367, 223–231 (2016)
8.  Pratley RE et al., Curr Diabetes Rev 17, 14-27 (2021)
9. Cameron G et al., Obesity 26, 2047–2056 (2018)
10. Garg S et al., J Clin Endocrinol Metab 103, 4590–4598 (2018)
11.  Marso SP et al., Lancet Diabetes Endocrinol 6, 288-296 (2018)
12. Husain M et al., J Clin Invest 130, 665-674 (2020)
13. Choudhury S et al., J Clin Endocrinol Metab 105, e497–e505 (2020)
14. Dalsgaard EM et al., Obesity 24, 251–259 (2016)
15. Alberti KGMM et al., Lancet 366, 1652–1661 (2005)
16. Elbrønd B et al., Diabetes Obes Metab 17, 158–167 (2015)
17. Lingvay I et al., BMC Med 18, 331 (2020)
18. Vimalanathan S et al., J Clin Endocrinol Metab 101, 4159–4167 (2016)
19. Tominari A et al., J Gerontol A Biol Sci Med Sci 73, 676–684 (2018)
20. Mandal S et al., Endocrinology 161, 2251–2262 (2020)
21. Frias JP et al., J Diabetes Sci Technol 15, 145-157 (2021)
22. Marathe PH et al., Diabetes Obes Metab 21, 2199–2208 (2019)
23.   Aroda VR et al., J Clin Endocrinol Metab 100, 2349-2357 (2015)
24. Miquel E et al., J Gerontol A Biol Sci Med Sci 71, 1303–1312 (2016)
25. Larsen M et al., Endocrinol Diab Metab 4, e00201 (2021)

Peptide storage

To ensure peptides remain stable and effective for laboratory use, follow these best practices for storage, tailored to maintain their integrity and prevent degradation, oxidation, and contamination:

Short-Term Storage

• Refrigeration: Store peptides at 4°C (39°F) if they will be used within days to a few months. Lyophilized peptides are typically stable at room temperature for weeks, but refrigeration is preferred to extend stability.
• Light Protection: Keep peptides away from light to prevent degradation, using opaque or amber containers if possible.

Long-Term Storage

• Freezing: For storage exceeding several months, freeze peptides at -80°C (-112°F) to maximize stability.
• Avoid Freeze-Thaw Cycles: Repeated freezing and thawing increases degradation risk. Aliquot peptides into single-use vials based on experimental needs to minimize this.
• Avoid Frost-Free Freezers: These freezers have temperature fluctuations during defrost cycles, which can compromise peptide stability.

Preventing Oxidation and Moisture Contamination

• Minimize Air Exposure: Limit the time peptide containers are open to reduce oxidation, especially for peptides containing cysteine (C), methionine (M), or tryptophan (W), which are prone to air oxidation.
• Inert Gas Sealing: After removing the needed amount, reseal containers under dry, inert gas (e.g., nitrogen or argon) to prevent oxidation of remaining peptides.
• Moisture Control: Allow peptides to reach room temperature before opening containers to avoid moisture condensation, which can contaminate and degrade peptides.

Storing Peptides in Solution

• Avoid Long-Term Storage in Solution: Peptide solutions have a shorter shelf life and are susceptible to bacterial degradation. Lyophilized form is preferred for long-term storage.
• Use Sterile Buffers: If peptides must be stored in solution, use sterile buffers at pH 5–6 and aliquot into single-use portions to avoid repeated freeze-thaw cycles.
• Refrigeration for Solutions: Store solutions at 4°C (39°F) for 30–60 days. Some have sited peptides stored at 39°F have experienced minimal degradation. Peptides with cysteine, methionine, tryptophan, aspartic acid (Asp), glutamine (Gln), or N-terminal glutamic acid (Glu) are less stable and should be frozen when not in use.

Peptide Storage Containers

• Container Requirements: Use clean, clear, structurally sound, and chemically resistant containers sized appropriately for the peptide quantity.
• Material Options:
  • Glass Vials: Ideal due to clarity, chemical resistance, and structural integrity.
  • Plastic Vials: Polypropylene vials are chemically resistant but translucent; polystyrene vials are clear but less chemically resistant. Transfer peptides to glass if needed.
• Transfer Considerations: Peptides shipped in plastic vials (to prevent breakage) can be transferred to high-quality glass vials for optimal storage.

General Tips

• Store in a cold, dry, dark environment.
• Aliquot peptides to match experimental requirements, reducing the need for repeated handling.
• Avoid light exposure to prevent photodegradation.
• Minimize air exposure to reduce oxidation risks.
• Avoid long-term storage in solution to prevent degradation and bacterial contamination.

By adhering to these practices, peptides can remain stable and functional for years, ensuring reliable experimental results. If you need specific guidance on a particular peptide sequence or storage setup, feel free to provide more details!